Skip to main content
. 2020 Feb 12;29(155):190052. doi: 10.1183/16000617.0052-2019

FIGURE 2.

FIGURE 2

Summary of the technical properties and performances of the four main plasma genotyping platforms studied for early stage nonsmall cell lung cancer detection. #: early stages: hybrid capture, plasma next-generation sequencing (NGS) (16 genes) and 8 protein markers. : minimal residual disease (MRD): plasma NGS, patient-specific multiplex PCR (10 to 22 single-nucleotide variations), subclonal evolution. +: early stage MRD: hybrid capture, plasma NGS (139 genes). §: early stage MRD: hybrid capture, plasma NGS (58 genes).